ABSTRACT RNA interference (RNAi) mediated by smallinterfering RNAs (siRNAs) is a highly effective gene-silencing mechanism with great potential for gene-therapeutic applications. siRNA agents also exert non-target-related biological effects and toxicities, including immune-system stimulation. Specifically, siRNA synthesized from the T7 RNA polymerase system triggers a potent induction of type-I interferon (IFN) in a variety of cells. Singlestranded RNA also stimulates innate cytokine responses in mammals. We found that pppGn (n = 2,3) associated with the 5'-end of the shorthairpin RNA (shRNA) from the T7 RNA polymerase system did not induce detectable amounts of IFN. The residual amount of guanine associated with the 5'-end and hairpin structures of the transcript was proportional to the reduction of the IFN response. Here we describe a T7 pppGn (n = 2,3) shRNA synthesis that does not induce the IFN response, and maintains the full efficacy of siRNA.
INTRODUCTION
RNA interference (RNAi) is a natural biological phenomenon mediated by small-interfering RNA (siRNA) molecules that target-specific messenger RNA (mRNA) for degradation by cellular enzymes. RNAi has become the method of choice for studying gene function, especially in mammalian systems. With proof-of-concept studies already reported against a wide variety of human pathogens, and several innovative methods available for delivering siRNA to a range of primary cells, there is now an even greater role for siRNA as a potential therapeutic strategy. siRNAs induce the global upregulation of interferon (IFN)-stimulated gene expression (1) (2) (3) (4) , as shown by the transfection of both enzymatically and chemically synthesized siRNAs into cells, and by siRNAs that are produced intracellularly following the expression of short-hairpin RNAs (shRNAs) (2) (3) (4) . These studies documented significant non-specific changes in gene expression as a consequence of the delivery of siRNAs.
One simple method to limit the risk of inducing an IFN response is to use the lowest effective dose of the shRNA vector, as advocated by Bridge et al. (1) . Recently, Kim et al. (5) demonstrated that siRNAs synthesized using the T7 RNA polymerase system trigger a potent induction of IFN-a and IFN-b in a variety of cells. The mediator of this response is an initiating 5 0 -triphosphate that is required for IFN induction. These findings led to the development of an improved method for bacteriophage polymerase-mediated siRNA synthesis that incorporates two 3 0 -adenosines to prevent base-pairing with the initiating guanines, thereby allowing RNase T1 and calf intestine alkaline phosphatase (CIP) to remove the initiating 5 0 -nucleotides (nt) and triphosphates of the transcripts. It is now clear that triphosphates act as triggers to induce type I IFN via the activation of retinoic acid-inducible protein I (RIG-I) (6, 7) . By contrast, Marques et al. (8) reported that blunt siRNAs are potent activators of RIG-I-mediated type I IFN induction, whereas siRNAs containing 3 0 -overhangs are not. Here, we describe a new type of shRNA, pppGn(n = 2)-shRNA, synthesized by bacteriophage polymerase, which does not induce IFN. We also describe the anti-human immunodeficiency virus type 1 (HIV-1) activity of this shRNA, which targets the well-conserved dimerization initiation site (DIS) of HIV-1.
MATERIALS AND METHODS

RNAs
T7 shRNAs were synthesized using the AmpliScribe T7 High Yield Transcription Kit (Epicentre, Madison, WI) according to the manufacturer's protocol. For the in vitro transcription of RNA, T7 primer I (5 0 -TAATACGACTCACTATA-3 0 ) was hybridized with T7 primer II, which contains the antisense sequence of each transcribed RNA, the tail sequence (5 0 -CCTATA GTGAGTCGTATTA-3 0 ) and the loop sequence (5 0 -TC TCTTGAA-3 0 ). For example, to make pppGG-luc3-shRNA, two primers were used (5 0 -TAATACGACTC ACTATA-3 0 ) and (5 0 -AAGGAGCCTTCAGGATTACA AGATCTCTTGAATCTTGTAATCCTGAAGGCTCC CCTATAGTGAGTCGTATTA-3 0 ). After a 1-h at 378C, for the CIP, 50 U RNA (New England Biomedical, Beverly, MA) was added to the shRNA and incubated at 378C for 1 h. Finally, the shRNAs and siRNA were purified by polyacrylamide gel electrophoresis (PAGE).
Cell culture
HeLa CD4
+ cells were grown in RPMI 1640 medium (Sigma Chemical Co., St Louis, MO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin.
Assays for IFN
The amount of IFN-b secreted into the growth medium was determined using IFN ELISA kits (PBL Biomedical Laboratories, Piscataway, NJ). HeLa CD4 + or RIG-I silencing HeLa CD4 + cells were transfected with 100 nM shRNAs or siRNA using DMRIE-C (Invitrogen, San Diego, CA) according to the manufacturer's protocol, and were placed in 12-well plates. After 90 min, the cells were washed with RPMI-1640. Medium from RNAtransfected HeLa CD4
+ cells was collected 12 h later, serially diluted and assayed for the amount of secreted IFN according to the manufacturer's protocol. Each assay was performed in triplicate. Antibody neutralization assays were carried out by diluting the medium to 3.3% with fresh medium and mixing with 100 U/ml IFN-b neutralizing antibody (PBL Biomedical Laboratories) for 1 h.
Dual-luciferase reporter assay
HeLa CD4
+ cells in 12-well plates were co-transfected with 0.2 mg firefly luciferase vector, pGL3 control vector or pNL 4-3 -luc, and 0.2 mg pRG-TK control vector containing Renilla luciferase (Promega Corp. Madison, WI) using FuGENE TM 6 (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's protocol. shRNAs were used at a concentration of 12.5-50 nM per well. Firefly and Renilla luciferase activities were measured consecutively using dual-luciferase assays (Promega) 48 h after transfection.
Assay of HIV-1 replication
HIV-1 production was monitored by determining the HIV-1 p24 antigen concentration. HeLa CD4 + cells were transfected with shRNAs or LacZ (control shRNA) using DEMRI-C (Invitrogen). After 90 min, the cells were washed with serum-free RPMI-1640 and then transfected with pNL 4-3 using FuGENE TM 6 (Roche Diagnostics) according to the manufacturer's protocol. The culture medium from HeLa CD4 + cells was harvested 2 days post-transfection. p24 Gag protein production was detected by the HIV-1 p24 chemiluminescent enzyme immunoassay (CLEIA; Lumipulse, Fujirebio Inc., Tokyo, Japan), according to the manufacturer's protocol (9) .
Dual-luciferase reporter assay of IRF-3 activity
HeLa CD4
+ cells were seeded at a density of 1 Â 10 5 cells per well into 12-well plates for 24 h, and then transfected with 0.5 mg pIRF-3/Luc DNA (10) and 0.2 mg phRG-TK using FuGENE TM 6 (Roche Diagnostics) according to the manufacturer's protocol. After 24 h, 100 nM shRNA or 0.5 mg/ml polyinosinic acid:polycytidylic acid (poly I:C) was transfected using DMRIE-C (Invitrogen). Untreated cells were used as a control. Firefly and Renilla luciferase activities were measured consecutively using dualluciferase assays (Promega Corp.) 12 h after transfection.
MTS assay
HeLa CD4
+ cells (2 Â 10 4 cells/ml) were seeded into 96-well microtitre plates and incubated in the presence of various concentrations of the test compounds. The dilutions ranged from one-fold to five-fold, and nine concentrations were examined. All of the experiments were performed in triplicate. After 3 days culture at 378C in a CO 2 incubator, cell viability was quantified by a colorimetric assay monitoring the ability of viable cells to reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS; Promega Corp.) to a red formazan product (11) . The absorbances were read by a microcomputercontrolled photometer (Titertec MultiscanR; Labsystem Oy, Helsinki, Finland) at a single wavelength (492 nm). These values were then translated into percentages per well.
RNA interference in HeLa CD4
+ cells
HeLa CD4 + cells were transfected with 100 nM siRNAs targeting RIG-I (sense CGAUUCCAUCACUAUCC AUtt; antisense, AUGGAUAGUGAUGGAAUCGtt; Sigma Aldrich Japan, Hokkaido, Japan) using DMRIE-C (Invitrogen) according to the manufacturer's protocol, and were placed in 12-well plates.
Reverse-transcription polymerase chain reaction (RT-PCR)
Total cellular RNA was prepared using TRIZOL (Invitrogen). RIG-ImRNA was detected by a RT-PCR High-Plus kit (Toyobo, Kyoto, Japan) with the following specific primers: RIG-I sense, 5 0 -TCCTTTATGAGTAT GTGGGCA-3 0 ; and RIG-I antisense, 5 0 -TCGGGCACA GAATATCTTTG-3 0 . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primers were used as a loading control in a separate reaction. The reaction parameters were 2 min at 948C, followed by 40 cycles of 1 min at 948C and 1.5 min at 608C.
RESULTS
pppGn(n = 2)-shRNA does not induce IFN
To investigate the RNAi-mediated silencing of luciferase activity, we initially synthesized six shRNAs targeting the luciferase gene transcript using T7 RNA polymerase. The main advantages of this technique are its simplicity and low cost compared with chemical synthetic RNA (12, 13) . The luc-shRNAs include a 5 0 -pppGn (n = 2) sequence, because efficient T7 RNA polymerase initiation requires the first and second non-transcribed spacer of each RNA to be a guanine.
To determine whether pppGn(n = 2)-shRNA-luc specifically inhibited luciferase gene expression, HeLaCD4 + cells ( Figure 2C ), whereas minor cellular toxicity was induced by pppGn(n = 0,1)-shRNA-luc3.
The antiviral activities of IFN have been recently studied (14) , but our data indicate that the presence of a guanine residue on T7-transcribed RNAs prevents the activation of IFN. Furthermore, the inhibition of luciferase activity by pppGn(n = 0)-shRNA-luc3 (Figure 2A -C) might be due, in part, to IFN induction. These results suggest that the residual amount of guanine associated with the 5 0 -end of the transcript is proportional to the reduction of the IFN response.
Inhibition of HIV-1 replication by shRNAs synthesized using T7 RNA polymerase
To confirm the role of residual guanine, we tested the sequence-specific inhibition of HIV-1 replication by shRNAs synthesized using the T7 RNA polymerase. We applied the shRNA technology to a well-conserved target in HIV-1: the dimerization initiation site (DIS) (15, 16) . The DIS is a stem-loop structure with six selfcomplementary nt at the top ( Figure 3A) , which is located between the primer binding site and the splice donor site at the end of a long terminal repeat (LTR) (17) . It is involved in the dimerization of the HIV-1 genome, packaging and proviral synthesis (18) (19) (20) (21) (22) . There are two major motifs in HIV-1: GUGCAC in subtypes A and C, and GCGCGC in subtypes B and D (23,24) . The subtype A motif has been shown to be a good siRNA target in an in vitro cell-free system where HIV-1 genome dimerization was successfully inhibited by a 9-mer DIS-targeting siRNA, while the corresponding DNA oligonucleotide did not affect dimerization (25, 26) . These studies also showed that sense oligonucleotides function as competitive inhibitors of this self-complimentary target.
pppGn(n = 2)-shRNA-DIS (shRNA-DIS-1-8) targeted against the 35-nt stem-loop (nt 248-277) or the 9-nt loop of the DIS (nt 255-263) were tested for their ability to inhibit HIV-1 replication ( Figure 3B ). The effect of shRNA-DIS-1-8 on HIV-1 (pNL 4-3 -luc) (27) replication was measured in a transient assay following its co-transfection with pNL 4-3 -luc into HeLa CD4 + cells. At 48 h post-transfection, luciferase activity was measured with the dual-luciferase reporter (DLR TM ) assay system. The luciferase activity of the cell lysate was measured as an indirect marker of viral replication. Although shRNA-DIS-3, shRNA-DIS-7 and shRNA-DIS-8 had strong inhibitory effects compared with shRNA-DIS-1 and shRNA-DIS-2, their anti-HIV-1 activities were lower than those of shRNA-DIS-4, shRNA-DIS-5 and shRNA-DIS-6 ( Figure 3C ). The internal control, pppGn(n = 2)-shRNA-LacZ targeting LacZ protein, did not inhibit luciferase activity.
Sequence-specific inhibition of HIV-1 replication by T7 transcribed shRNA-DIS-6
To further investigate the specific effect of shRNA-DIS6 on the DIS sequence, we examined shRNA-DIS-6 and the internal control shRNA-LacZ against infection by HIV-1 NL4-3 ( Figure 4A ). The shRNA-DIS effect was confirmed as specific to the DIS gene, because no obvious effects were observed following the HIV-1 NL4-3 challenge.
We pppGn(n = 0,2)-shRNA-DIS-6 were then co-transfected into HeLa CD4 + cells. IRF-3 activation was monitored using the DLR TM assay ( Figure 4C ). The internal control, polyI:C and pppGn(n = 0)-shRNA-DIS6 simultaneously induced phosphorylation of IRF-3 and luciferase gene expression in HeLa CD4 + cells. By contrast, pppGn(n = 2)-shRNA-DIS6 and HOGn(n = 0)-shRNA-DIS6 did not mediate either IRF-3 phosphorylation or luciferase gene expression in these cells ( Figure 4C ).
To further clarify the RIG-I-mediated IFN response to pppGn(n = 0,2)-shRNA, we used RNAi to specifically target RIG-I in HeLa CD4 + cells. After 2 days, cells were transfected with shRNAs [pppGn (n = 0,2) or HOGn(n = 0)-shRNA-DIS6] using DMRIE-C, and the IFN ELISA assay were carried out. However, pppGn (n = 0,2)-shRNA-DIS6 and HOGn(n = 0)-shRNA-DIS6 strongly inhibited INF-b production ( Figure 4D ). These data indicate that pppGn(n = 0)-shRNA induced an RIG-I-mediated INF response, whereas pppGn(n = 2)-shRNA arrested INF-inducing activity through TLR-3 and RIG-I.
We next monitored cell growth. The pppGn(n = 0)-shRNA-DIS6-transfected cells showed cytopathogenic effects after 3 days, but the pppGn(n = 2)-shRNA-DIS6-transfected cells did not ( Figure 4E ). Finally, we used the MTS assay to examine the viability of pppGn(n = 0,2)-shRNA-DIS-6-transfected HeLa CD4 + cells. HOGn (n = 2)-shRNA-DIS-6 and pppGn(n = 2)-shRNA-DIS-6 or LacZ did not induce cellular toxicity ( Figure 4E ), whereas control polyI:C and pppGn(n = 0)-shRNA-DIS-6 did ( Figure 4F ). Together, these data indicate that the residual guanine associated with the 5 0 -end and the hairpin-loop structures of the transcript is proportional to the reduction of the IFN response.
DISCUSSION
The present study demonstrates that the previously proposed scheme of triphosphate-dependent siRNA recognition (5) is, in fact, reversed; although T7-transcribed-siRNA induced a vigorous type I IFN response, 5 0 OH-siRNA did not. Our studies raise the question of how the residual guanine that is associated with the 5 0 -end of the transcript contributes to reducing the IFN response. To investigate the RNAi-mediated silencing of luciferase activity, we synthesized shRNA-luc, including the 5 0 -pppGn (n = 0-3) sequence, because efficient T7 RNA polymerase initiation requires the first and second non-transcribed space of each RNA to be a guanine. The pppGn (n = 2,3) associated with the 5 0 -end of shRNA does not induce IFN in HeLa CD4 + cells (Figure 2A ), whereas the IFN response was weakly initiated by the pppGn (n = 1) associated with the 5 0 -end of the shRNA. The pppGn (n = 0) associated with the 5 0 -end of the shRNA more potently induced IFN than the pppGn (n = 1) associated with the 5 0 -end of the shRNA. Furthermore, 5 0 -HOGn (n = 0-3) did not induce IFN in HeLa CD4 + cells. Our results suggest that the residual amount of guanine associated with the 5 0 -end of the transcript is proportional to the reduction of the IFN response. In another study, T7-transcribed siRNAs triggered a potent induction of IFN-a and IFN-b in a variety of cells, and the mediator of this response was an initiating 5 0 -triphosphate that was required for IFN induction (5). More recently, two groups reported that type I IFN is induced by the activation of RIG-I by 5 0 -triphosphate RNA (6,7). It will be important to re-examine these data in light of the possibility that these RNAs contain triphosphates, which complicates the interpretation. Our data indicate that 5 0 -triphosphates are responsible for inducing IFN activity, whereas the residual amount of guanine associated with the 5 0 -end of the transcript arrests the IFN response. To reconfirm the role of the residual amount of guanine associated with the 5 0 -end of the shRNA, we tested the sequence-specific inhibition of HIV-1 replication by shRNAs synthesized using T7 RNA polymerase. The HIV genome is a homodimer of two sense RNA single strands. We applied the shRNA technology to a well-conserved target in HIV-1, the DIS (15, 16) . The pppGn(n = 2)-shRNA-DIS6, as the target of the DIS gene, was a more potent inhibitor than the other types of shRNA-DIS. The synthesized pppGn(n = 2)-shRNA-DIS6 did not induce the activation of IFN ( Figure 4B ), but not the pppGn(n = 0)-shRNA-DIS6 and pppGn(n = 2)-siRNA-DIS6. Furthermore, the activation of IRF-3 did not induce with the pppGn(n = 2)-shRNA-DIS6 and HOGn(n = 0)-shRNA-DIS6, but not the pppGn(n = 0)-shRNA-DIS6 ( Figure 4C ). However, RIG-I-siRNA transfected cells which did not stimulation of IFN by both pppGn (n = 0) or pppGn(n = 2)-shRNA-DIS6 ( Figure 4D) . Recently, it was demonstrated that the pppGGG associated with short double-stranded RNA (dsRNA; pppGGG-dsRNA) is recognized by RIG-I but not TLR-3 (5, 6) . In contrast, the pppGn(n = 2)-shRNA-DIS6 also included pppGGG on the 5 0 -end of the shRNA, but did not recognize TLR-3 and RIG-I ( Figure 4B-D) . Furthermore, pppGn(n = 2)-shRNA-DIS6 presented a hairpin-loop structure together with the 5 0 -pppGGG, but not the presence on pppGGGdsRNA. Hence, the pppGGG dsRNA was capable of inducing IFN (5, 6) , but the pppGn(n = 2)-shRNA-DIS6 with the guanine associated with the 5 0 -end and the hairpin-loop structures precluded the IFN response. One study suggested that synthetic short dsRNA with blunt ends is recognized by RIG-I, and that 2-nt overhangs at the 3 0 -end block this recognition (7) . Taken together, these data indicate that the mechanism of inducing IFN by dsRNA with 5 0 -pppGGG can differentiate between dsRNAs with or without the guanine associated with the 5 0 -end and hairpin-loop structures. These results demonstrated an association with sequence-specific inhibition via the RNAi mechanism.
In conclusion, shRNAs transcribed by T7 RNA polymerase activate cells of the immune system cells and induce IFN production. However, the presence of a triphosphate on in vitro-transcribed RNAs can induce activation of the immune system (5). The pppGn (n = 2-3) associated with the 5 0 -end of the shRNA from T7 RNA polymerase did not induce detectable IFN, whereas pppGn (n = 0,1) associated with the 5 0 -end of the shRNA did induce IFN. Importantly, the residual amount of guanine associated with the 5 0 -end and the hairpin-loop structures of the transcript was proportional to the reduction of the IFN response. The improved method of T7 RNA polymerase-mediated shRNA synthesis did not require RNase treatment to remove the initiating 5 0 -nt and triphosphates of the transcripts. Our identification of a putative immunostimulatory motif with shRNAs provides a basis for the rational design of synthetic shRNAs that avoid inducing an immune response. This finding will help to reduce the potential for off-target gene effects.
